Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2650)	1/5/2010 4:30:26 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

BCRX did almost close its July 17 UG and has now started to move to the upside.<g> The stock is up 8.3% with volume > 2M close to its ADV. bigcharts.marketwatch.com The pending 4thQ results are still not expected to show a good comparison with previous Yr., but after that things are expected to improve as the EE by Thomson-Reuters is around $0.02 on the black for 2010 vs. the expected loss around $0.80 for the current Yr. Back on Oct 23. BCRX announced that the FDA had issued an emergency use authorization for i.v. peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital. And on November 5, BCRXt sold 10,000 courses of peramivir at $2,250 each to the U.S. Department of Health and Human services. The price per course is justified when a day in the Intensive Care Unit on a ventilator can cost upwards of $30,000. BCRX will report that $22.5M sale as revenue in the Dec Q. BCRX has been burning its cash at a good clip, but in Nov. it had an offering of 5M shares of its common stock at $9.75 with gross proceeds of $48.75M Woll see how it will handle the resistance above $10 <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2650)	2/2/2010 2:23:22 PM
From: Jibacoa	Respond to of 3722

ACHN was up 18.59% at its intraday H at 11:54AM and 12:04PM It is still up 12.81% in spite of that intraday double top, with the help of some upticks as I am writting this note.<g> The stock traded above its Jan19 H, and it already has closed its Dec16 UG. Volume of > 2,394,700 is almost 4x its ADV bigcharts.marketwatch.com It announced that it has entered a partnership to develop and sell its hepatitis B and HIV drug candidate elvucitabine in China and other territories. Yesterday it announced a marketing partnership with GCA Therapeutics. The terms were not disclosed, but the companies said GCA will have the right to develop and sell elvucitabine in China, Hong Kong, and Taiwan through a joint venture with Tianjing Institute of Pharmaceutical Research. ACHN could receive milestone payments if the drug passes through testing and review, and royalty payments of more than 10% on sales in those areas.<g> Bernard

To: Jibacoa who wrote (2650)	2/2/2010 2:23:23 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ACHN was up 18.59% at its intraday H at 11:54AM and 12:04PM It is still up 12.81% in spite of that intraday double top, with the help of some upticks as I am writting this note.<g> The stock traded above its Jan19 H, and it already has closed its Dec16 UG. Volume of > 2,394,700 is almost 4x its ADV bigcharts.marketwatch.com It announced that it has entered a partnership to develop and sell its hepatitis B and HIV drug candidate elvucitabine in China and other territories. Yesterday it announced a marketing partnership with GCA Therapeutics. The terms were not disclosed, but the companies said GCA will have the right to develop and sell elvucitabine in China, Hong Kong, and Taiwan through a joint venture with Tianjing Institute of Pharmaceutical Research. ACHN could receive milestone payments if the drug passes through testing and review, and royalty payments of more than 10% on sales in those areas.<g> Bernard